Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LXRX vs SANA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SANA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

SANA Overall Winner 6-Pillar Tally: LXRX 2 – 3 SANA (1 Tie) Matrix Metrics: LXRX 4 – 4 SANA

As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LXRX vs SANA
LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
Pharmaceutical Preparations
$1.75
-2.23% 1D
Market Cap $797.0M
TTM Revenue $39M
Forward P/E N/M
Beta / 30D Vol 0.63β · 60% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 5.0 Fund 33.0 Flow 65.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.2 · SMA20: $1.60 · SMA50: $1.76
SANA NASDAQ Head-to-Head Winner
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68

6-Pillar Scorecard Institutional Category Breakdown (LXRX 2 – 3 SANA)

Columns: Metric · LXRX · SANA
1. Valuation Multiples LXRX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 20.9x N/M
2. Growth & Scale SANA
Revenue Growth (YoY) -20.7% +0.0%
Earnings Growth (YoY) -63.4% +0.0%
TTM Revenue (USD) $39M N/A
Market Cap $797.0M $605.3M
3. Profitability & Quality SANA
Gross Margin 91.4% N/A
Operating Margin -147.4% 0.0%
Net Profit Margin -161.8% 0.0%
Return on Equity (ROE) -43.9% -79.5%
4. Balance Sheet & Cash Flow LXRX
Cash Generation (TTM) -$49M -$145M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.5M Net Debt (0.33x D/E) $13M Net Debt (0.30x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SANA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 78.4% (8th %ile) 105.5% (4th %ile)
Put/Call OI Skew N/A 0.61x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LXRX (4) vs SANA (4)
Institutional Metric LXRX SANA Criterion Row Edge
Market Capitalization
Scale
$797.0M $605.3M Larger Scale LXRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-20.7% +0.0% Higher Growth SANA
Operating Margin (TTM)
Profitability
-147.4% 0.0% Higher Margin SANA
Net Profit Margin
Profitability
-161.8% 0.0% Higher Margin SANA
Return on Equity (ROE)
Capital Efficiency
-43.9% -79.5% Higher ROE LXRX
52-Week Range Position
Momentum
41% ($1–$3) 1% ($2–$5) Stronger Trend LXRX
Beta / 30D Volatility
Risk Regime
0.63β · 60% Vol 1.82β · 78% Vol Lower Realized Risk LXRX
Unified Institutional Score
Composite Signal
38.7 / 100 (SELL) 44.3 / 100 (HOLD) Higher Composite SANA
Trailing 12M Revenue (USD)
Operating Scale
$39M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
91.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 20.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$49M ($9.5M Net Debt (0.33x D/E)) -$145M ($13M Net Debt (0.30x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LXRX +32.31 pp
LXRX: +15.13% · SANA: -17.18%
3M Horizon LXRX +20.52 pp
LXRX: -27.69% · SANA: -48.21%
6M Horizon LXRX +19.94 pp
LXRX: -18.22% · SANA: -38.16%
1Y Horizon LXRX +70.16 pp
LXRX: +21.53% · SANA: -48.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LXRX vs SANA. Trailing 12-month operating profitability (LXRX -147.4% vs SANA 0.0%) and valuation multiples (LXRX N/M vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LXRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin91.4%
Op. Margin-147.4%
ROE / Fwd P/E-43.9% · N/M
SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LXRX BREAKDOWN
98d in phase · OBV ACCUMULATION
Current IV 78.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LXRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 105.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LXRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $797.0M market capitalization and -147.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LXRX vs SANA Key Questions & Quantitative Answers

As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) is the stronger overall head-to-head candidate over Lexicon Pharmaceuticals, Inc. (LXRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LXRX carries a Unified Composite Score of 38.7/100 (SELL) at $1.75 (N/M Forward P/E, -147.4% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: LXRX is currently in a Breakdown options structure phase (RSI 54.2); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SANA leads the Growth & Scale pillar: LXRX posts -20.7% YoY revenue growth and -63.4% YoY earnings growth on $39M TTM revenue (91.4% gross margin, -147.4% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LXRX generates $39M in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, LXRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.

LXRX screens cheaper on headline valuation multiples. LXRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 20.9x EV/Revenue (unreported FCF margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LXRX (-43.9% ROE) versus SANA (-79.5% ROE) capital efficiency.

In options market volatility and institutional positioning, LXRX carries 78.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.63β · 60% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.